Literature DB >> 9417501

[Role of sodium selenite as an adjuvant in radiotherapy of rectal carcinoma].

T Hehr1, W Hoffmann, M Bamberg.   

Abstract

BACKGROUND: In various epidemiologic studies an association of low selenium blood levels and reduced glutathione peroxidase with an increased risk of cancer incidence was described. The antitumoral therapy and a suboptimal nutrition could intensify this deficiency. Every reduction of disease related and therapeutic caused symptoms may improve life quality. APPLICATION: We report our preliminary experiences in the adjuvant radiochemotherapy of advanced rectal cancer (UICC II/III) corresponding to the NCl recommendation. An oral selenium supplementation was carried out with 2000 micrograms Na2SeO3 after every course of fluorouracil chemotherapy and daily 400 micrograms Na2SeO3 after irradiation of tumor region and lymph nodes. A weekly life quality assessment was explored with special interest in diarrhea, dysurie, pain, appetite, nausea and emesis.
CONCLUSION: Damages to normal tissue specially to DNA enzymes and membranes caused by free radicals is one mechanism in tumorgenesis, tumor progression and therapeutic consequence. A radioprotective effect of selenium is verified by in vitro and in vivo data. Our data show that oral selenium intake in rectal cancer patients is easily tolerated with no side effects. Improving life quality and secondary cancer prevention with supplementation of selenium has to be proven in prospective randomized studies.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9417501     DOI: 10.1007/bf03041966

Source DB:  PubMed          Journal:  Med Klin (Munich)        ISSN: 0723-5003


  9 in total

1.  Combined modality radioprotection: the use of glucan and selenium with WR-2721.

Authors:  M L Patchen; T J MacVittie; J F Weiss
Journal:  Int J Radiat Oncol Biol Phys       Date:  1990-05       Impact factor: 7.038

2.  Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group.

Authors:  L C Clark; G F Combs; B W Turnbull; E H Slate; D K Chalker; J Chow; L S Davis; R A Glover; G F Graham; E G Gross; A Krongrad; J L Lesher; H K Park; B B Sanders; C L Smith; J R Taylor
Journal:  JAMA       Date:  1996-12-25       Impact factor: 56.272

Review 3.  Prospective study of toenail selenium levels and cancer among women.

Authors:  M Garland; J S Morris; M J Stampfer; G A Colditz; V L Spate; C K Baskett; B Rosner; F E Speizer; W C Willett; D J Hunter
Journal:  J Natl Cancer Inst       Date:  1995-04-05       Impact factor: 13.506

4.  Erythrocyte glutathione peroxidase in patients with colon cancer.

Authors:  A Jendryczko; M Pardela; A Kozlowski
Journal:  Neoplasma       Date:  1993       Impact factor: 2.575

5.  Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery.

Authors:  M J O'Connell; J A Martenson; H S Wieand; J E Krook; J S Macdonald; D G Haller; R J Mayer; L L Gunderson; T A Rich
Journal:  N Engl J Med       Date:  1994-08-25       Impact factor: 91.245

6.  Is the changing pattern of colorectal cancer caused by selenium deficiency?

Authors:  R L Nelson
Journal:  Dis Colon Rectum       Date:  1984-07       Impact factor: 4.585

7.  Selenium pretreatment enhances the radioprotective effect and reduces the lethal toxicity of WR-2721.

Authors:  J F Weiss; R L Hoover; K S Kumar
Journal:  Free Radic Res Commun       Date:  1987

8.  Blood selenium concentrations and glutathione peroxidase activities in patients with breast cancer and with advanced gastrointestinal cancer.

Authors:  Z Pawłowicz; B A Zachara; U Trafikowska; A Maciag; E Marchaluk; A Nowicki
Journal:  J Trace Elem Electrolytes Health Dis       Date:  1991-12

9.  Risk of cancer in relation to serum concentrations of selenium and vitamins A and E: matched case-control analysis of prospective data.

Authors:  J T Salonen; R Salonen; R Lappeteläinen; P H Mäenpää; G Alfthan; P Puska
Journal:  Br Med J (Clin Res Ed)       Date:  1985-02-09
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.